Actions Of Vanilloids In The Nucleus Of The Solitary Tract
Funder
National Health and Medical Research Council
Funding Amount
$196,527.00
Summary
Capsaicin, the active ingredient of hot chillies, and other pungent plant extracts have been used for millennia to relieve minor pain. We now know that these agents produce pain relief (analgesia) by numbing the very nerve cells (neurons) which transmit pain signals to the brain. The unique analgesic properties of vanilloids may have a place in modern medicine, giving relief to sufferers of certain types of chronic pain (e.g., neuropathic pain) which are not responsive to morphine-like analgesic ....Capsaicin, the active ingredient of hot chillies, and other pungent plant extracts have been used for millennia to relieve minor pain. We now know that these agents produce pain relief (analgesia) by numbing the very nerve cells (neurons) which transmit pain signals to the brain. The unique analgesic properties of vanilloids may have a place in modern medicine, giving relief to sufferers of certain types of chronic pain (e.g., neuropathic pain) which are not responsive to morphine-like analgesics. Indeed, the promise of more potent and less pungent vanilloid analgesics has led to the discovery of numerous naturally-occurring and synthetic vanilloids. However, although the neurons which convey information regarding blood pressure and the oxygen content of arterial blood to control centres in the brain stem are also stimulated by vanilloids, the central (brain stem) actions of vanilloids on blood pressure and respiration have not been investigated in detail. Thus, the aim of this project is to describe the characteristics of vanilloid receptors in the brain stem, determine the acute and chronic effects of naturally-occurring and synthetic vanilloids on blood pressure and respiration, and elucidate the role played by other neurotransmitter chemicals in the actions of vanilloids. The results of these studies will have major implications in the future use of vanilloids as analgesics.Read moreRead less
Novel Approaches To The Targeting Of GPCRs Towards Improved Treatment Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
The focus of these studies are two important types of brain proteins that have been implicated in various symptoms associated with schizophrenia. The aim is to exploit two emerging paradigms of drug action at these brain proteins that will allow us to target them in a more selective manner. In particular, these studies will provide a starting point for safer, more effective treatments for schizophrenia.
A Breakdown Of Cortical Homeostasis In Depression: A Focus On The Anterior Cingulate
Funder
National Health and Medical Research Council
Funding Amount
$625,629.00
Summary
Major depressive disorders affect 20% of the Australian population. Some symptoms of major depressive disorders arise because of a dysfunction of the human brain, particularly the cortex. Our studies show there are biochemical changes in the anterior cingulate cortex in people with mood disorders. We will now extend our studies to show there is a breakdown in the balance between neurotransmitter and neuroinflammation pathways in the anterior cingulate cortex in major depressive disorders.
Rational Co-targeting Of G Protein-coupled Receptors As A Novel Approach Towards Treating Neuropsychiatric Disorders
Funder
National Health and Medical Research Council
Funding Amount
$620,399.00
Summary
Schizophrenia is a common mental disorder with multiple symptoms. Current therapeutics only treat some of these symptoms. This project will focus on two important brain proteins implicated in schizophrenia. With the hypothesis that the rational targeting of these two proteins will lead to the design of more effective medicines for treatment of schizophrenia we will develop novel methods to selectively and simultaneously and target these two proteins.